PTP4A3 and cancer: At present, somewhat of a consensus exists suggesting that deregulated levels of PRL-3 expression share a strong correlation with cancer progression and poor survival, whereas postulations have been made highlighting its ability as a potential biomarker and therapeutic target in cancer.44